Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.28), Zacks reports.
Bicara Therapeutics Price Performance
Shares of NASDAQ:BCAX remained flat at $14.47 on Friday. The stock had a trading volume of 594,520 shares, compared to its average volume of 488,219. Bicara Therapeutics has a twelve month low of $8.91 and a twelve month high of $28.09. The business has a 50-day moving average of $12.81 and a 200 day moving average of $15.25.
Institutional Trading of Bicara Therapeutics
A hedge fund recently bought a new stake in Bicara Therapeutics stock. AQR Capital Management LLC acquired a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 19,034 shares of the company's stock, valued at approximately $248,000.
Analyst Ratings Changes
A number of research firms have commented on BCAX. Stifel Nicolaus set a $48.00 target price on Bicara Therapeutics in a research report on Thursday, March 27th. HC Wainwright decreased their target price on Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating on the stock in a research report on Friday. Wells Fargo & Company began coverage on Bicara Therapeutics in a research report on Thursday, April 17th. They set an "underweight" rating and a $8.00 target price on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Finally, Wedbush reiterated an "outperform" rating and set a $31.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Bicara Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $32.00.
Read Our Latest Report on BCAX
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Further Reading
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
